A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA) as a Second-line Therapy in NSCLC Patients

Trial Profile

A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA) as a Second-line Therapy in NSCLC Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2012

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms SELINE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Jan 2009 Actual end date added, as reported by ClinicalTrials.gov.
    • 01 Jan 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 29 Sep 2008 Planned end date changed from 1 Jul 2008 to 1 Mar 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top